Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Repana D"'
Autor:
Beddowes, E, Spicer, J, Chan, PY, Khadeir, R, Corbacho, JG, Repana, D, Steele, JP, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomson, J, Sheaff, M, Wu, B-W, Bomalaski, J, Pacey, S, Szlosarek, PW
Publikováno v:
Beddowes, E, Spicer, J, Chan, P Y, Khadeir, R, Garcia Corbacho, J, Repana, D, Steele, J P, Schmid, P, Szyszko, T, Cook, G, Diaz, M, Feng, X, Johnston, A, Thomason, J, Scheaff, M, Wu, B-W, Bomalaski, J, Pacey, S & Szlosarek, P W 2017, ' Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers ', Journal of Clinical Oncology, vol. 35, no. 16, pp. 1778-1785 . https://doi.org/10.1200/JCO.2016.71.3230
Purpose: Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) -negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recomm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d3b5e67f628e85c2d09fcd2d9019a2
https://kclpure.kcl.ac.uk/ws/files/72158703/Phase_1_Dose_Escalation_Study_BEDDOWES_Publishedonline7April2017_GOLD_VoR_CC_BY_.pdf
https://kclpure.kcl.ac.uk/ws/files/72158703/Phase_1_Dose_Escalation_Study_BEDDOWES_Publishedonline7April2017_GOLD_VoR_CC_BY_.pdf
Autor:
Hyphantis, T., Papadimitriou, I., Petrakis, Dimitrios, Fountzilas, George, Repana, D., Assimakopoulos, K., Carvalho, A. F., Pavlidis, Nicholas
Publikováno v:
Psycho-oncology
Objective Psychiatric manifestations and personality traits are known to influence cancer patients. We aimed to assess psychological distress symptoms, psychosocial factors and health-related quality of life (HRQoL) in cancer of unknown primary site
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______4485::be7e99d7b4a2c00f5e860251b95fa309
https://gnosis.library.ucy.ac.cy/handle/7/41956
https://gnosis.library.ucy.ac.cy/handle/7/41956
Autor:
Fountzilas, G., Kourea, H. P., Bobos, M., Televantou, D., Kotoula, V., Papadimitriou, C., Papazisis, K. T., Timotheadou, E., Efstratiou, I., Koutras, A., Pentheroudakis, G., Christodoulou, C., Aravantinos, G., Dimosthenis Miliaras, Petraki, K., Papandreou, C. N., Papakostas, P., Bafaloukos, D., Repana, D., Razis, E., Pectasides, D., Dimopoulos, A. M.
Publikováno v:
Scopus-Elsevier
Europe PubMed Central
Europe PubMed Central
BACKGROUND: Randomized studies have shown that bevacizumab combined with taxane-based regimens increases response rates and prolongs progression-free survival (PFS) of patients with metastatic breast cancer (MBC). However predictive or prognostic bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c1b8401d1836efc77e33f1cf821a52e5
https://pubmed.ncbi.nlm.nih.gov/21868552
https://pubmed.ncbi.nlm.nih.gov/21868552
Autor:
Ross, P.J., Repana, D., Saunders, M., Wilson, R.H., Plummer, C.J., Summers, J., Higgins, F., Peacock, J., Harari, D., Bridgewater, J.
Publikováno v:
In European Journal of Cancer February 2017 72 Supplement 1:S69-S70
Publikováno v:
European Journal of Surgical Oncology; Sep2016, Vol. 42 Issue 9, p1331-1336, 6p
Autor:
Repana, D.1 (AUTHOR), Shanmugalingam, T.1 (AUTHOR), Gerrard, G.2 (AUTHOR), Foot, N.2 (AUTHOR), Kulkarni, A.2 (AUTHOR), Naidoo, K.2 (AUTHOR), Talukdar, S.2 (AUTHOR), Snape, K.2 (AUTHOR), Hanson, H.2 (AUTHOR), Quigley, K.2 (AUTHOR), Mokretar, K.2 (AUTHOR), Du Parcq, P.2 (AUTHOR), Ferguson, B.2 (AUTHOR), Sarker, D.2 (AUTHOR), Murugaesu, N.2 (AUTHOR)
Publikováno v:
Annals of Oncology. 2022 Supplement 8, Vol. 33, pS1393-S1393. 1p.
Autor:
Papazisis, K., Boukovinas, I., Repana, D., Stergiou, E., Kontovinis, L., Papakotoulas, P., Kouvatseas, G.
Publikováno v:
In European Journal of Cancer March 2012 48 Supplement 1:S114-S114
Autor:
Novellasdemunt L; Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Kucharska A; Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Baulies A; Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Hutton C; Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Vlachogiannis G; Centre for Molecular Pathology, the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK., Repana D; Cancer Systems Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Rowan A; Cancer Evolution and Genome Instability Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Suárez-Bonnet A; Pathobiology and Population Sciences, Royal Veterinary College, Hatfield AL9 7TA, UK; Experimental Histopathology, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Ciccarelli F; Cancer Systems Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK., Valeri N; Centre for Molecular Pathology, the Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK., Li VSW; Stem Cell and Cancer Biology Laboratory, the Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK. Electronic address: vivian.li@crick.ac.uk.
Publikováno v:
Stem cell reports [Stem Cell Reports] 2023 Feb 14; Vol. 18 (2), pp. 570-584. Date of Electronic Publication: 2023 Jan 19.
Autor:
Lockwood N; Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London, UK., Martini S; Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London, UK., Lopez-Pardo A; Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London, UK., Deiss K; Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London, UK., Segeren HA; Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London, UK., Semple RK; Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK., Collins I; Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK., Repana D; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, UK.; School of Cancer and Pharmaceutical Sciences King's College London, New Hunt's House, Guy's Campus, London, UK., Cobbaut M; Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London, UK., Soliman T; Barts Cancer Institute, Queen Mary University London, Charterhouse Square, London, UK., Ciccarelli F; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, UK.; School of Cancer and Pharmaceutical Sciences King's College London, New Hunt's House, Guy's Campus, London, UK., Parker PJ; Protein Phosphorylation Laboratory, The Francis Crick Institute, 1 Midland Road, London, UK.; School of Cancer and Pharmaceutical Sciences King's College London, New Hunt's House, Guy's Campus, London, UK.
Publikováno v:
Cancer research [Cancer Res] 2022 May 03; Vol. 82 (9), pp. 1762-1773.
Autor:
Dressler L; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK.; Department of Medical and Molecular Genetics, King's College London, London, SE1 9RT, UK., Bortolomeazzi M; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Keddar MR; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Misetic H; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Sartini G; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Acha-Sagredo A; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Montorsi L; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Wijewardhane N; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Repana D; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Nulsen J; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK., Goldman J; Scientific Computing, The Francis Crick Institute, London, NW1 1AT, UK., Pollitt M; Scientific Computing, The Francis Crick Institute, London, NW1 1AT, UK., Davis P; Scientific Computing, The Francis Crick Institute, London, NW1 1AT, UK., Strange A; Scientific Computing, The Francis Crick Institute, London, NW1 1AT, UK., Ambrose K; Scientific Computing, The Francis Crick Institute, London, NW1 1AT, UK., Ciccarelli FD; Cancer Systems Biology Laboratory, The Francis Crick Institute, London, NW1 1AT, UK. francesca.ciccarelli@crick.ac.uk.; School of Cancer and Pharmaceutical Sciences, King's College London, London, SE11UL, UK. francesca.ciccarelli@crick.ac.uk.
Publikováno v:
Genome biology [Genome Biol] 2022 Jan 26; Vol. 23 (1), pp. 35. Date of Electronic Publication: 2022 Jan 26.